NCT05534217

Brief Summary

Patients who signed informed consent to participate in the study will receive corneal epithelial deplasia. The patient was instructed to follow up closely in the following year, and the recurrence of the patient was collected through wechat follow-up.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
156

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 5, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 9, 2022

Completed
4 months until next milestone

Study Start

First participant enrolled

December 31, 2022

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
Last Updated

September 9, 2022

Status Verified

September 1, 2022

Enrollment Period

8 months

First QC Date

August 5, 2022

Last Update Submit

September 6, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • wound recurrence

    Wound recurrence during 12 months after treatment.

    month 12 after treatment

Secondary Outcomes (3)

  • Incidence of wound infection

    week 1, week 2, month 1, month 2, month 3, month 6, month 9, and month 12.

  • The grading of pain for eyes

    week 1, week 2, month 1, month 2, month 3, month 6, month 9, and month 12.

  • Corneal scar

    week 1, week 2, month 1, month 2, month 3, month 6, month 9, and month 12.

Study Arms (2)

debridement+traditional treatment

EXPERIMENTAL

The experimental group receives debridement of the abrasion wound before receiving traditional treatment including evofloxacin eye drops + befushu QID \* for 14 days, four times a day, and the corneal contact lens was worn for 2 weeks.

Biological: corneal debridement of corneal abrasion

traditional treatment

ACTIVE COMPARATOR

The traditional group receives evofloxacin eye drops + befushu QID \* for 14 days, four times a day, and the corneal contact lens was worn for 2 weeks.

Biological: corneal debridement of corneal abrasion

Interventions

Surgical debridement for traumatic corneal epithelial abrasions

debridement+traditional treatmenttraditional treatment

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • The affected eye is traumatic corneal epithelial abrasion, and the specific criteria are as follows: A: Damage caused by one of the three high risk causes of recurrent corneal epithelial exfoliation defined as fingernails, paper, or plant leaves; B: Monocular disease; C: Eye pain, tears, photophobia and foreign body sensation when injured; D: Local defect of corneal epithelium was found at the time of injury, and fluorescein sodium staining was positive; E: The time from injury to first diagnosis is less than 24 hours.
  • Be between the ages of 18 and 60.
  • Patients volunteered to participate in the study and signed the informed consent, showing good compliance.

You may not qualify if:

  • Corneal epithelial defect complicated with infection.
  • Patients with other ocular surface diseases (such as eyelid insufficiency, eyelid gland dysfunction, Sjogren's syndrome, bullae keratopathy, corneal dystrophy, drug induced corneal toxicity, etc.).
  • Pre-existing corneal disease (corneal degenerative disease or viral keratitis, etc.) or history of corneal surgery;
  • Long-term contact lens wearers.
  • Pregnant or lactating women; Severe impairment of heart, liver and kidney function; One who is mentally abnormal; People with other inflammatory or autoimmune diseases. Corneal epithelial defect complicated with infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhaohui Yuan

Guangzhou, Guangdong, 510000, China

Location

MeSH Terms

Conditions

Corneal Injuries

Condition Hierarchy (Ancestors)

Eye InjuriesFacial InjuriesCraniocerebral TraumaTrauma, Nervous SystemNervous System DiseasesCorneal DiseasesEye DiseasesWounds and Injuries

Central Study Contacts

Zhaohui Yuan, Doctor's degree

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
The participants didn't know where they were grouped,and the experimenters did not know about the trial either.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Patients diagnosed with traumatic corneal epithelial abrasions are treated by complete debridement of the corneal epithelium
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 5, 2022

First Posted

September 9, 2022

Study Start

December 31, 2022

Primary Completion

September 1, 2023

Study Completion

January 1, 2024

Last Updated

September 9, 2022

Record last verified: 2022-09

Data Sharing

IPD Sharing
Will not share

Locations